Gonadotropin-Releasing Hormone-Antagonist in Human In Vitro Fertilization

Gonadotropin-releasing hormone antagonists (GnRH-nt) available for clinical use are GnRH molecules with amino acid modifications in positions 1, 2, 3, 6, and 10. They are not associated with the histaminic-release effects of previous compounds (1). These compounds immediately block GnRH receptor in a competitive fashion (2). They decrease the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion within a period of eight hours. Inhibition of LH secretion is more important than FSH. This is probably due to the different forms of gonadotropin regulation, the prolonged FSH half-life, or the immunoactive and bioactive forms of FSH (3,4). . | _5_ Gonadotropin-Releasing Hormone-Antagonist in Human In Vitro Fertilization F. Olivennes Department of Obstetrics and Gynecology Hospital Cochin Paris France INTRODUCTION Gonadotropin-releasing hormone antagonists GnRH-nt available for clinical use are GnRH molecules with amino acid modifications in positions 1 2 3 6 and 10. They are not associated with the histaminic-release effects of previous compounds 1 . These compounds immediately block GnRH receptor in a competitive fashion 2 . They decrease the luteinizing hormone LH and follicle-stimulating hormone FSH secretion within a period of eight hours. Inhibition of LH secretion is more important than FSH. This is probably due to the different forms of gonadotropin regulation the prolonged FSH half-life or the immunoactive and bioactive forms of FSH 3 4 . Administered during the follicular phase GnRH-nt can prevent or interrupt LH surges 5 . In addition their use has been proposed in in vitro fertilization IVF -embryo transfer ET cycles to obtain results similar to those obtained with GnRH-a however with the simplest protocol and fewer side effects 6 . Two different compounds are available the Cetrorelix Cetrotide formerly ASTA Medica now Serono and the Ganirelix Antagon or Orgalutran Organon . Two different protocols of administration Fig. 1 have been proposed in the literature for using GnRH-nt in controlled 67 68 Olivennes Figure 1 Gonadotropin-releasing hormone antagonist multiple- and single-dose protocols. Fixed day regimens. Abbreviations FSH follicle-stimulating hormone hMG human menopausal gonadotropin hCG human chorionic gonadotropin. ovarian stimulation COH . In the multiple-dose protocol small doses mg of the GnRH-nt are injected in the middle of the follicular phase 7-9 . In the single-dose protocol a higher dose 3 mg is injected during the late follicular phase when the LH surge is most feared 10 11 . PHASE II DOSE-FINDING STUDIES Single-Dose .

Không thể tạo bản xem trước, hãy bấm tải xuống
TÀI LIỆU MỚI ĐĂNG
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.